J&J pays up for Pfizer consumer unit error
In 2006, Johnson and Johnson acquired a plant in Lititz, PA when it bought Pfizer's consumer health care division. Now federal lawmakers contend that the plant violated paperwork regulations for controlled substances in Pennsylvania during the preceding five years, from 2001 to 2005.
Pseudophedrine is the controlled substance under question, and authorities allege that Prizer's consumer unit imported Benadryl-D, which contains pseudophedrine, from Canada without officially notifying the US Drug Enforcement Agency under the Controlled Substances Act. The Act requires companies to provide written notification of importation of any controlled substances.
J&J settled the case; it will pay $511,000 to the federal government because of the error.
- check out the story at CNN Money
- read the Pharmalot blog post
- get more from the Wall Street Journal
- check out the US Department of Justice statement
Related Articles:
FDA panel to mull decongestant changes
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

